Charles Chau is a partner in Morrison & Foerster’s Hong Kong office. He focuses in providing advice on mergers and acquisitions, listings and public offerings, capital markets transactions, securities regulatory compliance, joint ventures, and other commercial transactions across Hong Kong, mainland China, and the Asia-Pacific region.
Mr. Chau has extensive experience across a wide variety of industry sectors, including banking and financial services, health care, biotech, retail, real estate, and manufacturing. Over the years, Mr. Chau has represented clients in more than 100 public and private company acquisitions, joint ventures, financings, and pre-IPO investment, including acting for China CNR Corporation Limited in its US$26 billion merger with CSR Corporation Limited, being the first merger of two companies listed in both Hong Kong and Shanghai. He has also represented Chinese companies on their outbound acquisitions in the United States. On the capital markets side, Mr. Chau has worked on many IPOs and securities placement transactions. Representative matters include the IPOs of Sinopharm Group, China CNR Corporation, Guodian Technology and Environment Group Corporation Limited, as well as the A+H rights issue of China CITIC Bank.
Mr. Chau has been named as a leading practitioner for Equity Capital Markets by Chambers Asia Pacific 2016, as well as a recommended practitioner for Equity Capital Markets in Hong Kong and Real Estate in China by Legal 500 Asia Pacific 2016.
Mr. Chau holds offices in various public bodies, including serving as an Adjudicator of the Registration of Persons Tribunal and a committee member of the Legal Committee and the Young Executive Club of the Hong Kong General Chamber of Commerce.
Mr. Chau speaks fluent English, Cantonese, and Mandarin.
Charles Chau is ranked as a leading lawyer by Chambers Asia-Pacific 2016 and is also recommended by Legal 500 Asia Pacific 2016.
©1996-2016 Morrison & Foerster LLP. All rights reserved.